New target combined with Tamoxifen aids in ER-positive breast cancers
Researchers have identified compounds used in some leukemia treatments that may have an application towards ER positive breast cancer that is unresponsive to traditional treatments.
The discovery was made at the Walter and Eliza Hall Institute. BH3-mimetics were effective in treating aggressive oestrogen receptor-positive breast cancers when combined with the breast cancer drug tamoxifen in preclinical models. Approximately 70 per cent of breast cancers are ER positive.
"Drs Vaillant and Merino looked at the effect of adding BH3-mimetics to the standard hormone treatment, tamoxifen, used for a subtype of ER-positive cancers called luminal B cancers, which had high levels of BCL-2," said Professor Lindeman . "They found that a BH3-mimetic called ABT-199/GDC-0199 improved the effectiveness of hormone therapy by stopping or delaying the growth of these aggressive tumours. In one of the tumour models, the combined treatment caused complete disappearance of the tumour, while standard treatment had only a partial and unsustained benefit."
The new target, BCL-2, is responsible for suppressing a cancer cells desire to apoptose, or kill itself.
Read more: [url]http://www.cell.com/cancer-cell/abstract/S1535-6108(13)00282-1
Last edited by gdpawel : 07-15-2013 at 08:15 AM.
Reason: posted full article in forum board